PHP8 A COMPARISON OF POLICIES ON PAEDIATRIC DOSING GUIDELINES AND INDICATIONS BETWEEN THE UNITED STATES AND EUROPE
Nixon F, Chan M, Lock K F F Heron Evidence Development Ltd, Luton, UK OBJECTIVES: To compare legislation on paediatric dosing guidelines and indications between the US and Europe and to examine whether the introduction of new regulations and fi nancial incentives has resulted in more pharmaceutical companies providing paediatric data. METHODS: Information was extracted from published policies and reports on paediatric therapeutics as published by the US Food and Drug Administration and the European Medicines Agency. RESULTS: In the US, the Food and Drug Administration Modernisation Act (FDAMA; 1997) offered six months of marketing exclusivity to manufacturers voluntarily conducting paediatric studies. Current legislation in the US consists of the Best Pharmaceuticals for Children Act (BPCA; 2002) , and the Paediatric Research Equity Act (PREA; 2003) . Manufacturers are also encouraged to obtain orphan drug designation for drugs or biological products for use in a paediatric population. To January 2008, the FDA has sent written requests for paediatric studies to sponsors of 301 drugs. There have been 157 incidents of labeling changes under the BPCA and 76 labeling changes or submissions of supporting information under the PREA. Legislation on paediatric therapeutics was issued in the EU in January 2007 (Regulation (EC) No 1901 No /2006 . Since this time, the EMEA has adopted decisions on 99 applications for paediatric investigational plans (PIPs) and waivers; 57 positive opinions on PIPs; 3 proposed modifi cations to PIPs; and 39 waivers in all age groups for all conditions. Additionally, most European Health Technology Assessment agencies do not make special allowances for the assessment of paediatric therapeutics and dosing. CONCLUSIONS: The introduction of legislation in the US has been successful in encouraging research into the use of therapeutics in paediatric patients. In the EU, although many applications of PIPs and waivers have been reviewed, the situation should be monitored over the coming years to determine if the legislation leads to changes.
PHP9 THE IMPACT OF LEGISLATION AND PRICING ON GENERIC DRUG UTILIZATION: AN ANALYSIS OF 26 COUNTRIES
Patorno E, Margulis A, Cai S, Gagne JJ, Geisler BP, Li Q, Lin SW, Liu W, Palmsten K, Yau WP, Polinski JM Harvard School of Public Health, Boston, MA, USA OBJECTIVES: Across countries with varying political, socioeconomic and cultural environments, we sought to identify predictors of generic drug utilization. METHODS: Data were collected from national and international regulatory agencies, MEDLINE and internet searches for 37 countries classifi ed as "advanced" or "emerging" economies by the International Monetary Fund: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, India, Ireland, Israel, Italy, Japan, Luxembourg, Malta, Mexico, Netherlands, New Zealand, Norway, Portugal, Russia, San Marino, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, UK, United States. We compared the presence of generic policies, fi rst year of generic legislation, branded drug patent duration, proportion of generic drug utilization, and pricing for generics (government control, free market, or other), gross domestic product, and population across countries. Only independent variables with p 0.20 in univariate regression were included in the multivariate model: population, year of generic legislation, patent life, and pricing for generics (market vs. government control). RESULTS: Of 37 countries, data was available for 26 (70%): Argentina, Australia, Austria, Brazil, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Portugal, Russia, Singapore, Spain, Sweden, Switzerland, UK and United States. Most countries enacted generic drug legislation in the 1990s, 9 (35%) introduced legislation before 1990, and 3 (12%) after 2000. Branded drug patent duration was 15-20 years for 65% of countries. Among countries with generic drug laws, only free market-based generic pricing, compared to government-controlled pricing, was associated with a nominal increase in generic drug utilization (B 0.17, 95% CI 0.01, 0.35). CONCLUSIONS: Countries with free market pricing policies had minimally greater diffusion of generic drugs compared to countries with government pricing controls. Further investigation of other characteristics, namely the political and social climates that foster greater generic drug utilization is planned. , and taking medications for any of the following conditions: hypertension, hyperlipidemia, diabetes, asthma/COPD, or depression. RESULTS: In this initial phase, 69 patients were enrolled and 24 (34.8%) reported reaching the coverage gap in 2007. Among in-gap patients, 95% were aged 65-85 years and 58% were female, compared to 73% and 64% respectively for the no-gap subjects. Compared with the no-gap subjects, more in-gap subjects attended college (78% vs. 46%), had a monthly income of $2000 or more (70.8% vs. 56%), and spent more than $300 per month on medications (42% vs. 24%). Compared with no-gap patients, in-gap patients were less likely (54% vs. 69%) to report overall satisfaction with Part-D programs. Finally, 87.5% of the in-gap patients reached the gap in September 2007 or later. CONCLU-SIONS: One-third of the subjects reached the coverage gap and most of them reached the gap within the last quarter of 2007, mitigating the impact of coverage gap to some extent. The in-gap group belonged to higher socioeconomic status, which was expected since the no-gap group appeared not to be at the risk of coverage gap because of low-income subsidies. Experiencing coverage gap negatively impacted patients' satisfaction with Part-D plans.
PHP10 CHARACTERISTICS OF MEDICARE PART-D ENROLLEES WITH AND WITHOUT PRESCRIPTION DRUG COVERAGE GAP

PHP11 THE IMPACT OF NON-REFERRAL OUTPATIENT CO-PAYMENT ON MEDICAL CARE UTILISATION AND EXPENDITURE IN TAIWAN
Chen LC 1 , Schafheutle E 2 , Noyce P 2 , Wen YH 1 , Wu JS 3 1 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2 University of Manchester, Manchester, UK, 3 Bureau of National Health Insurance, Kaohsiung, Taiwan OBJECTIVES: Taiwan's National Health Insurance's (NHI) generous coverage and patients' freedom to access different tiers of medical facilities has resulted in accelerating outpatient care utilisation and cost. To deter non-essential visits and encourage initial contact in primary care, a differential co-payment was introduced on July 15, 2005. Under this, patients pay more for outpatient consultations at higher medical facilities, particularly if accessed without referral. This study aimed to explore the impact of this policy on outpatient medical activities and expenditure, different copayment groups and tiers of medical facilities. METHODS: A segmented time-series analysis on regional weekly outpatient medical claims (January 2004 to July 2006). Outcome variables (number of visits, number of outpatients, total cost of outpatient care) and variables for cost structure were stratifi ed by tiers of medical facilities and
